PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.44%
EBIT growth below 50% of TRVN's 34.42%. Michael Burry would suspect deeper competitive or cost structure issues.
10.44%
Operating income growth under 50% of TRVN's 34.42%. Michael Burry would be concerned about deeper cost or sales issues.
10.28%
Net income growth under 50% of TRVN's 35.19%. Michael Burry would suspect the firm is falling well behind a key competitor.
12.12%
EPS growth under 50% of TRVN's 40.08%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
10.49%
Diluted EPS growth under 50% of TRVN's 40.08%. Michael Burry would worry about an eroding competitive position or excessive dilution.
2.21%
Share reduction more than 1.5x TRVN's 7.99%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.06%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-28.93%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4997.65%
Negative 10Y OCF/share CAGR while TRVN stands at 54.85%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
52.56%
5Y OCF/share CAGR at 50-75% of TRVN's 77.51%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
56.42%
3Y OCF/share CAGR at 50-75% of TRVN's 78.51%. Martin Whitman would suspect weaker recent execution or product competitiveness.
-10058.37%
Negative 10Y net income/share CAGR while TRVN is at 72.25%. Joel Greenblatt sees a major red flag in long-term profit erosion.
92.69%
5Y net income/share CAGR similar to TRVN's 90.06%. Walter Schloss might see both on parallel mid-term trajectories.
51.37%
3Y net income/share CAGR 50-75% of TRVN's 83.21%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
741.48%
10Y equity/share CAGR above 1.5x TRVN's 430.12%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
108.54%
Positive 5Y equity/share CAGR while TRVN is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
-89.94%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-17.83%
Negative asset growth while TRVN invests at 7.65%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-40.69%
We have a declining book value while TRVN shows 3.45%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
499.58%
Debt growth far above TRVN's 33.24%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-14.73%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
3.54%
We expand SG&A while TRVN cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.